Recent Updates
Recently added Catalysts

Propranolol

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 24, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment198

FDA Designations

No designations recorded

Clinical trial landscape

Propranolol · 2 trials · 1 indication

Phase 1 2
NCT00647608Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mgHealthy
COMPLETED98 Analytics
NCT00647816Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mgHealthy
COMPLETED100 Analytics
PHASE1COMPLETED
Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
HealthyUnlock trial analytics
PHASE1COMPLETED
Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Bioequivalence
within 30 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
1EXPERIMENTALPropranolol Hydrochloride Extended-Release Capsules 160 mg
2ACTIVE_COMPARATORInderal® LA Capsules 160 mg

Interventions

NameTypeDescription
Propranolol Hydrochloride Extended-Release Capsules 160 mgDRUG160mg, single dose fed
Inderal® LA Capsules 160 mgDRUG160mg, single dose fed
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have a negative serum (Beta HCG) pregnancy test performed within 21 days prior to the start of the study and on the evening prior to each dose administ...

Countries:United States
Unlock Eligibility Criteria